FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977993386> ?p ?o ?g. }

• W2977993386 endingPage "v351" @default.
• W2977993386 startingPage "v351" @default.
• W2977993386 abstract "Abstract Background Docetaxel is an established treatment for pts with mCRPC. Docetaxel plus the programmed death 1 (PD-1) inhibitor pembro and prednisone had activity in patients treated with abi or enza for mCRPC in the phase 1b/2 KEYNOTE-365 study (NCT02861573). KEYNOTE-921 (NCT03834506) is a randomized phase 3 trial to evaluate efficacy and safety of pembro plus docetaxel and prednisone in chemotherapy-naive pts who were previously treated with enza- or abi for mCRPC and had progression while on therapy. Trial design Adult (≥18 y) pts with chemotherapy-naive histologically or cytologically confirmed mCRPC who had progression while on androgen deprivation therapy (or postbilateral orchiectomy) within 6 months before screening were eligible. Pts must have had progression after ≥8 wk (≥14 wk for those with bone progression) or become intolerant after ≥4 wk of abi or enza treatment (but not both) with androgen-deprivation therapy in the chemotherapy-naive mCRPC state. Pts must have ECOG PS 0/1, adequate organ function, and tissue for biomarker analysis. Pts will be randomly assigned 1:1 to receive docetaxel 75 mg/m2 every 3 wks (Q3W) plus prednisone/prednisolone 5 mg twice daily (BID) and pembro 200 mg Q3W or docetaxel 75 mg/m2 Q3W plus prednisone/prednisolone 5 mg BID plus placebo Q3W. Treatment will be stratified per prior next-generation hormonal agent treatment (abi/enza) and metastases (bone only/liver/other). Responses will be assessed by CT/MRI and radionuclide bone imaging per PCWG3-modified RECIST v1.1 by blinded independent central review Q9W during the first year and Q12W thereafter. Treatment will continue with docetaxel and prednisone for up to 10 cycles and with pembro for up to 35 cycles or until radiographic disease progression, unacceptable toxicity, or consent withdrawal. Primary end points: overall survival and radiographic progression-free survival. The key secondary efficacy end point is time to initiation of subsequent anticancer therapy or death; safety and tolerability will also be reported. Approximately 1000 pts will be enrolled. Clinical trial identification NCT03834506; February 8, 2019. Editorial acknowledgement Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Legal entity responsible for the study Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Disclosure D.P. Petrylak: Advisory / Consultancy, Research grant / Funding (institution): Ada Cap (Advanced Accelerator Applications); Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy: Exelixis; Research grant / Funding (institution): Endocyte; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Innocrin; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Genentech; Advisory / Consultancy: Janssen, Pharmacyclics, Urogen; Research grant / Funding (institution): MedImmune, Merck; Research grant / Funding (institution): Novartis, Progenics, Sanofi Aventis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Roche Laboratories, Seattle Genetics; Shareholder / Stockholder / Stock options: Bellicum, Tyme. B. Li: Full / Part-time employment: Merck & Co., Inc. C. Schloss: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. K. Fizazi: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Orion; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer." @default.
• W2977993386 created "2019-10-10" @default.
• W2977993386 creator A5006619074 @default.
• W2977993386 creator A5007779528 @default.
• W2977993386 creator A5050042851 @default.
• W2977993386 creator A5059978899 @default.
• W2977993386 date "2019-10-01" @default.
• W2977993386 modified "2023-10-02" @default.
• W2977993386 title "KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)" @default.
• W2977993386 doi "https://doi.org/10.1093/annonc/mdz248.048" @default.
• W2977993386 hasPublicationYear "2019" @default.
• W2977993386 type Work @default.
• W2977993386 sameAs 2977993386 @default.
• W2977993386 citedByCount "3" @default.
• W2977993386 countsByYear W29779933862021 @default.
• W2977993386 countsByYear W29779933862023 @default.
• W2977993386 crossrefType "journal-article" @default.
• W2977993386 hasAuthorship W2977993386A5006619074 @default.
• W2977993386 hasAuthorship W2977993386A5007779528 @default.
• W2977993386 hasAuthorship W2977993386A5050042851 @default.
• W2977993386 hasAuthorship W2977993386A5059978899 @default.
• W2977993386 hasBestOaLocation W29779933861 @default.
• W2977993386 hasConcept C121608353 @default.
• W2977993386 hasConcept C126322002 @default.
• W2977993386 hasConcept C143998085 @default.
• W2977993386 hasConcept C2776421732 @default.
• W2977993386 hasConcept C2776551883 @default.
• W2977993386 hasConcept C2777701055 @default.
• W2977993386 hasConcept C2778720950 @default.
• W2977993386 hasConcept C2780057760 @default.
• W2977993386 hasConcept C2780192828 @default.
• W2977993386 hasConcept C2781190966 @default.
• W2977993386 hasConcept C61367390 @default.
• W2977993386 hasConcept C71924100 @default.
• W2977993386 hasConceptScore W2977993386C121608353 @default.
• W2977993386 hasConceptScore W2977993386C126322002 @default.
• W2977993386 hasConceptScore W2977993386C143998085 @default.
• W2977993386 hasConceptScore W2977993386C2776421732 @default.
• W2977993386 hasConceptScore W2977993386C2776551883 @default.
• W2977993386 hasConceptScore W2977993386C2777701055 @default.
• W2977993386 hasConceptScore W2977993386C2778720950 @default.
• W2977993386 hasConceptScore W2977993386C2780057760 @default.
• W2977993386 hasConceptScore W2977993386C2780192828 @default.
• W2977993386 hasConceptScore W2977993386C2781190966 @default.
• W2977993386 hasConceptScore W2977993386C61367390 @default.
• W2977993386 hasConceptScore W2977993386C71924100 @default.
• W2977993386 hasLocation W29779933861 @default.
• W2977993386 hasOpenAccess W2977993386 @default.
• W2977993386 hasPrimaryLocation W29779933861 @default.
• W2977993386 hasRelatedWork W122177069 @default.
• W2977993386 hasRelatedWork W1512914561 @default.
• W2977993386 hasRelatedWork W1652439388 @default.
• W2977993386 hasRelatedWork W1996389184 @default.
• W2977993386 hasRelatedWork W2077244514 @default.
• W2977993386 hasRelatedWork W2135620818 @default.
• W2977993386 hasRelatedWork W2400161037 @default.
• W2977993386 hasRelatedWork W2568045406 @default.
• W2977993386 hasRelatedWork W2602837880 @default.
• W2977993386 hasRelatedWork W2982156914 @default.
• W2977993386 hasVolume "30" @default.
• W2977993386 isParatext "false" @default.
• W2977993386 isRetracted "false" @default.
• W2977993386 magId "2977993386" @default.
• W2977993386 workType "article" @default.